Nouscom raises $13.5 million in Series A round

May 17, 2016 – BASEL. Nouscom announced today that it has closed a EUR 12 million ($13.5 million) Series A financing co-led by LSP and Versant Ventures. The funds will be used to support discovery and development of personalized cancer vaccines and tumor selective oncolytic viruses.

“We are pleased to partner with investors who support the development of a new immuno-oncology company. We have developed know-how and IP that puts Nouscom in a unique position to bring new new life-changing immunotherapeutic vaccines to cancer patients”, said Riccardo Cortese M.D., Ph.D., Chief Executive Officer and President of Nouscom.

Nouscom’s technology focuses on viral vectors and oncolytic viruses, which infect and kill tumor cells and stimulate an immune response against cancer cells throughout the body.  It has two product candidates, the Endovax and Exovax programs. Endovax, an antigenless vaccine, is based on oncolytic viruses capable of infecting and replicating only in cancer cells and causing immunogenic cell death, thereby recruiting T cells at the tumor site and reactivating T cells exhausted in the tumor micro-environment. Exovax is a personalized patient specific vaccine, based on viral vectors coding for strings of cancer neoantigens to induce and expand cancer and patient specific T cells.  

Nouscom Director Dr. Joachim (JR) Rothe says: “Personalized cancer vaccines and oncolytic “antigenless” vaccines have the potential to converge into a protocol of oncolytic virus prime- and personalized vaccine boost for maximum sustained effect.”

“The Nouscom platform offers an innovative approach to cancer vaccines that is versatile, powerful and scalable,” said Guido Magni, Partner at Versant Ventures.  ”Further, since we backed this same team at Okairos, we know the members’ skill level, dedication and ability to build a successful company.”

Source: Nouscom